Wednesday, 26 August 2026European Markets

BAM GROEP KON Stock Bullish Momentum With A 12.59% Jump Today

Loading stream...

(VIANEWS) - The Market ended the session with BAM GROEP KON (BAMNB.AS) rising 12.59% to €3.98 on Thursday while AEX-Index rose 0.01% to €884.17.

BAM GROEP KON's last close was €3.54, 0% below its 52-week high of €3.54.

About BAM GROEP KON

Koninklijke BAM Groep nv, together with its subsidiaries, provides products and services in the construction and property, civil engineering, and public private partnerships (PPP) sectors worldwide. The company engages in residential construction projects, and non-residential construction activities. It is also involved in rail infrastructure and facilities management activities. Koninklijke BAM Groep nv was founded in 1869 and is headquartered in Bunnik, the Netherlands.

Earnings Per Share

As for profitability, BAM GROEP KON has a trailing twelve months EPS of €0.64.

PE Ratio

BAM GROEP KON has a trailing twelve months price to earnings ratio of 6.22. Meaning, the purchaser of the share is investing €6.22 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.23%.

Moving Average

BAM GROEP KON's value is way above its 50-day moving average of €3.03 and way higher than its 200-day moving average of €2.36.

More news about BAM GROEP KON (BAMNB.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com